JAMA Network
About The Study: There is unlikely to be an increase in the very low incidence of suicide-related adverse events among individuals receiving glucagon-like peptide 1 receptor agonists (GLP-1 RAs) within the context of randomized clinical trials. While these findings may further ease concerns about these adverse effects, continued monitoring is warranted to identify particular patients who may be at risk as extended use of GLP-1 RAs expands.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
